Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen
The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
During 1985–1990 the U.S. National Cancer Institute (NCI) phased out its murine leukemia P388 anticancer drug screening program and developed as the replacement a new in vitro primary screen based upon a diverse panel of human tumor cell lines. For each substance tested, the screen generates a remarkably reproducible and characteristic profile of differential in vitro cellular sensitivity, or lack thereof, across the 60 different cell lines comprising the panel. Several investigational approaches to display, analysis, and interpretation of such profiles and databases, derived from the testing of tens of thousands of substances during the past 4–5 years since the NCI screen became fully operational, have been explored. A variety of useful, practical applications of the in vitro screen have become apparent. As these applications continue to evolve, they are proving to be complementary to diverse other anticancer screening and drug discovery strategies being developed or pursued elsewhere. Reviewed herein are some practical considerations and selected specific examples, particularly illustrating research applications of the NCI screen that may be more broadly applicable to the search for new anticancer drug development leads with novel profiles of antitumor activity and/or mechanisms of action. © 1995 Wiley‐Liss, Inc. This article is a US Government work and, as such, is in the public domain in the United States of America.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, in December 1992, MDA‐MB‐435 was added to the NCI‐60 cell line panel for use in anticancer drug screening, where it was initially described as a “breast” cancer cell line.17”
From Authentication of M14 melanoma cell line proves misidentification of MDA‐MB‐435 breast cancer cell line (2018) · cites this paper as [17]
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Self-citationMonks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Self-citationA Human Cell Line From a Pleural Effusion Derived From a Breast Carcinoma 2
Soule, H. D., Vazquez, J., Long, A., Albert, S., & Brennan, M. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1409 · Cited by 2,449
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Kaighn, M. E., Ks, N., Ohnuki, Y., Lechner, J. F., & Jones, L. W. (1979) · PubMed · Cited by 2,121
Breast Tumor Cell Lines From Pleural Effusions2
Cailleau, R., Young, R., Olivé, M., & Reeves, W. J. (1974) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/53.3.661 · Cited by 1,015
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 967
Self-citationRubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1113 · Cited by 927
Self-citationIsolation of a human prostate carcinoma cell line (DU 145)
Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., & Paulson, D. F. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910210305 · Cited by 926
Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization
Cailleau, R., Olivé, M., & Cruciger, Q. V. J. (1978) · In Vitro · doi:10.1007/bf02616120 · Cited by 679
Establishment and characterization of a cell line of human breast carcinoma origin
Keydar, I., Chen, L., Karby, S., Weiss, F. R., Delarea, J., Radu, M., Chaitcik, S., & Brenner, H. J. (1979) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(79)90139-7 · Cited by 650
Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T., & Bates, S. E. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09793-7 · Cited by 336
Self-citationNeural Computing in Cancer Drug Development: Predicting Mechanism of Action
Weinstein, J. N., Kohn, K. W., Grever, M. R., Viswanadhan, V. N., Rubinstein, L. V., Monks, A. P., Scudiero, D. A., Welch, L., Koutsoukos, A. D., Chiausa, A. J., et al. (1992) · Science · doi:10.1126/science.1411538 · Cited by 312
Self-citationHackett, A. J., Smith, H. S., Springer, E. L., Owens, R. B., Nelson-Rees, W. A., Riggs, J. L., & Gardner, M. B. (1977) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/58.6.1795 · Cited by 309
CANCER CHEMOTHERAPEUTIC AGENTS
Terezhalmy, G. T., Whitmyer, C. C., & Markman, M. (1996) · Dental Clinics of North America · doi:10.1016/s0011-8532(22)00132-x · Cited by 273
Antineoplastic agents. 257. Isolation and structure of spongistatin 1
Pettit, G. R., Chicacz, Z. A., Gao, F., Herald, C. L., Boyd, M. R., Schmidt, J. M., & Hooper, J. N. A. (1993) · The Journal of Organic Chemistry · doi:10.1021/jo00058a004 · Cited by 260
Self-citationAlvarez, M., Paull, K., Monks, A., Hose, C., Lee, J. S., Weinstein, J., Grever, M., Bates, S., & Fojo, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117910 · Cited by 216
Self-citationPaull, K. D., Lin, C. M., Malspeis, L., & Hamel, E. (1992) · PubMed · Cited by 194
Self-citationHeterotransplantation of a human prostatic adenocarcinoma cell line in nude mice.
Mickey, D. D., Stone, K. R., Wunderli‐Allenspach, H., Mickey, G. H., Vollmer, R. T., & Paulson, D. F. (1977) · PubMed · Cited by 171
Fuller, R. W., Cardellina, J. H., Kato, Y., Brinen, L. S., Clardy, J., Snader, K. M., & Boyd, M. R. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00094a012 · Cited by 171
Self-citation(1980) · PubMed · Cited by 154
Niederhuber, J. E. (1993) · B.C. Decker eBooks · Cited by 151
Bai, R., Cichacz, Z. A., Herald, C. L., Pettit, G. R., & Hamel, E. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13253-7 · Cited by 127
Anticancer Specificity of Some Ellipticinium Salts against Human Brain Tumors in vitro
Acton, E. M., Narayanan, V. L., Risbood, P. A., Shoemaker, R. H., Vistica, D. T., & Boyd, M. R. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00040a010 · Cited by 126
Self-citationStinson, S. F., Alley, M. C., Kopp, W. C., Fiebig, H., Mullendore, L. A., Pittman, A. F., Kenney, S., Keller, J., & Boyd, M. R. (1992) · PubMed · Cited by 119
Self-citationFuller, R. W., Cardellina, J. H., Jurek, J., Scheuer, P. J., Alvarado-Lindner, B., McGuire, M., Gray, G. N., Steiner, J. R., Clardy, J., & Menez, E. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00051a019 · Cited by 107
Pettit, G. R., Cichacz, Z. A., Gao, F., Herald, C. L., & Boyd, M. R. (1993) · Journal of the Chemical Society Chemical Communications · doi:10.1039/c39930001166 · Cited by 106
Self-citationCohen, J. S., Lyon, R. C., Chen, C., Faustino, P. J., Batist, G., Shoemaker, M., Rubalcaba, E., & Cowan, K. H. (1986) · PubMed · Cited by 99
Chromosomal analysis of human prostatic adenocarcinoma cell lines.
Ohnuki, Y., Marnell, M., Babcock, M. S., Lechner, J. F., & Kaighn, M. E. (1980) · PubMed · Cited by 87
Use of the Kohonen Self-organizing Map to Study the Mechanisms of Action of Chemotherapeutic Agents
van Osdol, W. W., Myers, T. G., Paull, K. D., Kohn, K. W., & Weinstein, J. N. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.24.1853 · Cited by 85
Self-citationPettit, G. R., Herald, C. L., Cichacz, Z. A., Gao, F., Schmidt, J. M., Boyd, M. R., Christie, N. D., & Boettner, F. E. (1993) · Journal of the Chemical Society Chemical Communications · doi:10.1039/c39930001805 · Cited by 77
Self-citationWeinstein, J. N., Myers, T. G., Buolamwini, J. K., Raghavan, K., van Osdol, W. W., Licht, J. D., Viswanadhan, V. N., Kohn, K. W., Rubinstein, L., Koutsoukos, A. D., et al. (1994) · Stem Cells · doi:10.1002/stem.5530120106 · Cited by 74
Self-citationData Display and Analysis Strategies for the NCI Disease-Oriented in Vitro Antitumor Drug Screen
Boyd, M. R., Paull, K. D., & Rubinstein-Achiasaf, L. (1992) · Springer eBooks · doi:10.1007/978-1-4615-3492-1_2 · Cited by 63
Self-citationKaighn, M. E., Kirk, D., Szalay, M., & Lechner, J. F. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5673 · Cited by 51
Antineoplastic Agents 293. The Exceptional Human Cancer Cell Growth Inhibitors Spongistatins 6 and 7
Pettit, G. R., Herald, C. L., Cichacz, Z. A., Gao, F., Boyd, M. R., Christie, N. D., & Schmidt, J. M. (1993) · Natural product letters · doi:10.1080/10575639308043871 · Cited by 49
Self-citationSiciliano, M. J., Barker, P. E., & Cailleau, R. (1979) · PubMed · Cited by 44
Kenney, S., Vistica, D. T., Linden, H., & Boyd, M. R. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00471-w · Cited by 19
Self-citationVistica, D. T., Kenney, S., Hursey, M. L., & Boyd, M. R. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1657 · Cited by 17
Self-citationExploratory data analytic techniques to evaluate anticancer agents screened in a cell culture panel
Hodes, L., Paull, K. D., Koutsoukos, A. D., & Rubinstein, L. (1992) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543409208835029 · Cited by 15
Self-citationPettit, G. R., Srirangam, J. K., Herald, D. L., Erickson, K. L., Doubek, D. L., Schmidt, J. M., Tackett, L. P., & Bakus, G. J. (1993) · The Journal of Organic Chemistry · doi:10.1021/jo00063a063 · Cited by 9
Editorial - "Mean Graphs" of NCI Screening Data
(1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00040a600 · Cited by 1
Research works printed but not linked: 6
- Acton EM, 1992, Anticancer specificity of some ellipticinium salts against human brain tumors in vitro, Proc Am Assoc Cancer Res, 33, 488
- Boyd MR, 1986, Accomplishments in Oncology, Vol 1, Cancer Therapy: Where Do We Go From Here?, 68
- Boyd MR, 1989, Cancer: Principles and Practice of Oncology Updates, 1
- Buolamwini JK, 1994, Searching for new molecular targets for therapy of cancer and AIDS: Characterization by 2D protein gel electrophoresis, Proc Am Assoc Cancer Res, 35, 613
- Grever MR, 1994, Status of in vivo evaluations in the NCI anticancer drug discovery program, Proc Am Assoc Cancer Res, 35, 369
- Stinson SF, 1992, Morphologic and immunocytochemical characteristics of human tumor cell lines for use in an anticancer drug screen, Anticancer Res, 12, 1035
Cited by
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,614
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Isolation and Synthesis of Biologically Active Carbazole Alkaloids
Knölker, H., & Reddy, K. R. (2002) · Chemical Reviews · doi:10.1021/cr020059j · Cited by 1,416
Impact of Natural Products on Developing New Anti-Cancer Agents
Cragg, G. M., Grothaus, P. G., & Newman, D. J. (2009) · Chemical Reviews · doi:10.1021/cr900019j · Cited by 1,302
Metadata
- Authors
- Boyd, M. R., & Paull, K. D.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Corresponding author
- Boyd, Michael R.
- ORCID
- Boyd, Michael R.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 1995-02
- Volume
- 34
- Issue
- 2
- Pages
- 91-109
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W2118909720
- Cited by
- 1,572
- References
- 40
- Citations by year
- 2026: 28 · 2025: 57 · 2024: 79 · 2023: 58 · 2022: 68 · 2021: 81 · 2020: 74 · 2019: 51 · 2018: 58 · 2017: 39 · 2016: 56 · 2015: 61 · 2014: 78 · 2013: 84 · 2012: 79
- FWCI
- 30.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Development Research (publishedVersion, public-domain)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- anticancer drug discovery, human cancer cell lines, anticancer activity, lead compound identification, mechanism of action
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.